Merck: KEYTRUDA And GARDASIL Sales Are Expected To Rise


  • In 2022, Merck’s KEYTRUDA and GARDASIL worldwide sales increased by 27% YoY.
  • The immunotherapy and HPV vaccines markets are expected to grow in the following years.
  • The company’s cash and capital structures show a significant improvement in 2022.
  • MRK stock is a buy.
HPV Vaccine

anilakkus/iStock via Getty Images

Merck & Co. (NYSE:MRK) stock price increased by 20% in the past six months. Year-to-date, the stock’s price has been relatively stable. The company reported full-year 2022 sales and net income of $59.3 billion and $14.5 billion, respectively, compared to full-year 2021 sales and net income of $48.7

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Leave a Reply

Your email address will not be published. Required fields are marked *